NZ start-up's ginger-based rheumatoid arthritis therapy in clinical trials

NZ start-up's ginger-based rheumatoid arthritis therapy in clinical trials
Evithé Biotechnology founder Cynthia Hunefeld. (Image: Supplied)
Greg Hurrell
A New Zealand start-up is carrying out phase one clinical trials of its rheumatoid arthritis therapy based on the ginger plant.Evithé Biotechnology is a spinout company from Victoria University developing botanical and multi-target pharmaceutical prescription drugs from ginger rhizomes.Beyond rheumatoid arthritis, the company has a pipeline of botanical and pharmaceutical prescription drugs that could get to the root of other inflammatory disorders such as Alzheimer’s disease and sepsis.It hopes to have its first therapies on the m...

More Editor's Picks

Neuren's 'embarrassment of opportunities'
Markets

Neuren's 'embarrassment of opportunities'

The pharmaceutical firm is pushing for approval of multiple phase-three trials in 2026.

Northland dairy goat farmers’ ‘beautiful dream’ sours
Primary Sector

Northland dairy goat farmers’ ‘beautiful dream’ sours

It was once worth over $24m. Now, they could be left with nothing.

Grocery delivery is booming: Woolworths NZ boss
Retail

Grocery delivery is booming: Woolworths NZ boss

The firm has invested heavily in optimising its delivery capability.

Gregor Thompson 06 May 2025
Cooper Investors' roller coaster run on Ryman
Property Analysis

Cooper Investors' roller coaster run on Ryman

The Aussie fund manager has lost millions on the retirement company.

Gregor Thompson 05 May 2025